Sanofi: Dupixent Data Show Sustained Improvement For Up To 2

PARIS (dpa-AFX) - Sanofi - Aventis Groupe of Sanofi (SNYNF, SNY) announced Monday that late-breaking Dupixent (dupilumab) data showed consistent efficacy and safety profile for up to two years

Related Keywords

Japan , Paris , France General , France , , International Congress , European Respiratory Society , European Union , Respiratory Society , Sanofi , Dupixent , Data , Show , Sustained , Improvement , Tears , Ith , Asthma ,